Company intelligence / Profile preview

RxMP Therapeutics

Miami, Florida, United Statesrxmp.squarespace.com ↗

Ownership: Private
Development stage: Preclinical

Overview

RxMP Therapeutics is developing RMP-HPEs, a novel class of systemically delivered hemostatic agents derived from red blood cells. Their lead candidate, RMP‑402, is in preclinical development and has shown promise in enhancing coagulation without increasing the risk of off-target thrombosis. The company recently entered a Cooperative Research and Development Agreement with the U.S. Department of Defense's Institute of Surgical Research to validate efficacy in large animal models.

Therapeutic areas: NeurologyHematology
Modalities: BiologicBlood and blood products (Red cell-derived microparticles)
Industry: Biotech

Drug pipeline

1 asset

RMP-402

Preclinical

Partnerships

U.S. Department of Defense Institute of Surgical Research (CRADA for preclinical validation)

Beyond the preview

Go deeper on RxMP Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RxMP Therapeutics.

Explore the full profile